We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biocartis Raises EUR 64.5 Million
News

Biocartis Raises EUR 64.5 Million

Biocartis Raises EUR 64.5 Million
News

Biocartis Raises EUR 64.5 Million

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biocartis Raises EUR 64.5 Million"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Biocartis has announced that it has successfully completed an EUR 64.5 million equity fundraising, one of the largest private rounds in the European life sciences industry in recent years.

The additional capital will fund the commercial roll-out of Idylla™ in Europe later this year, and the expansion of its commercial reach beyond Europe as of next year.

Furthermore, the fundraising will also support and accelerate the development of a wide range of diagnostic tests for Idylla™. With this round, the total capital invested in Biocartis to date amounts to EUR 240 million (approx. USD 316 million).

The capital round is subscribed by Johnson & Johnson Development Corporation, Hitachi Chemical Corporation, PMV Tina Fund and a few existing and new family offices.

Hilde Windels, CFO at Biocartis, stated: “We believe this major fundraising demonstrates the support for Biocartis’ ambition to make personalized medicine a truly sustainable, everyday practice. By intensifying the development of our assay menu, we intend to demonstrate the potential of Idylla™ in the field of oncology, infectious diseases and beyond. We thank our investors for their ongoing support and their belief in Biocartis’ groundbreaking role in transforming molecular diagnostics.”

Advertisement